Activity Provided By:

Integritas Communications

Making The Call in Lower-Risk MDS Exploring Treatments That Improve Outcomes & Decrease Transfusion Burden

Overview / Abstract:	Myelodysplastic syndromes (MDSs) are among the most common hematologic malignancies and are characterized by their risk of progression to acute leukemia. Although patients with lower-risk MDS (LR-MDS) have longer life expectancies compared to those with high-risk disease, their disease course is not without challenges. In fact, symptoms related to anemia are very common in this population and lead to poor quality of life. Fortunately, therapies are now available to treat the anemia associated with LR-MDS and improve outcomes across the spectrum of patient and disease profiles. In this Phone-a-Friend series, expert faculty will discuss the management of anemia in 4 different real-life clinical scenarios representative of the heterogeneous spectrum of LR-MDS.
Expiration	Aug 22, 2025
Format	Online, Webinar / Webcast / Video
Credits / Hours	1.0
Accreditation	ACCME
Presenters / Authors / Faculty	Andrew Kuykendall, MD Assistant Member, Malignant Hematology Department Moffitt Cancer Center and Research Institute Assistant Professor, Department of Oncologic Sciences University of South Florida Tampa, Florida Robert S. Ohgami, MD, PhD, FCAP Vice President, ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ Medical Director, Hematopathology Professor, University of Utah School of Medicine Salt Lake City, Utah Alyssa Mae de Castro, PharmD, BCOP Clinical Pharmacy Manager, Adult Stem Cell Transplantation and Cellular Therapy Department of Oncology Montefiore Medical Center Bronx, New York Aditi Shastri, MD Associate Professor Department of Oncology Department of Developmental & Molecular Biology Albert Einstein College of Medicine Montefiore Medical Center Bronx, New York
Sponsors / Supporters / Grant Providers	This activity is provided by Integritas Communications. This activity is supported by an independent educational grant from Bristol Myers Squibb.
Keywords / Search Terms	Integritas Communications Myelodysplastic syndromes, oncology, hematology Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map